The Arab Health Exhibition, the second-largest global medical exhibition, stands out as the largest and most comprehensive professional medical expo in the Middle East. Since its inaugural event in 1975, the exhibition has consistently expanded in scale, attracting professionals from around the world. Arab Health 2024 will continue to adopt a combined "online + offline" format, with the physical exhibition taking place from January 29 to February 1, 2024, providing more possibilities for exchanges in the medical field.
Themed "Innovation and Healthcare Reform" in Arab Health 2023, the exhibition showcased thousands of medical products and services, drawing 3,358 exhibiting companies from 76 countries and over 135,880 industry professionals globally. The exhibition not only achieved a satisfaction rate of 96% but also generated a substantial total business value of up to USD 1.081 billion.
The rapid growth in the medical and healthcare sector in the Middle East is becoming a crucial market for suppliers of medical equipment and pharmaceutical products. Investments are projected to grow at an annual rate of 9%, with the total investment expected to reach USD 55 billion by 2025. Gulf countries, in particular, plan extensive medical construction projects to meet the increasing demands in healthcare.
Arab Health 2024 encompasses a wide range of exhibits, including medical equipment and instrument devices, home healthcare products, and small healthcare instruments. Whether it is medical electronic instruments, medical X-ray equipment, or home health care products, all will receive ample exposure at the exhibition.
Arab Health 2024 will continue to provide a platform for innovation in the medical industry, driving the development of the medical equipment sector and injecting new momentum into the healthcare industry in the Middle East and globally.
Feellife Health Inc. was founded in 2013, headquartered in Shenzhen, and is recognized as a national high-tech enterprise. feellife® focuses on the research and development, production, marketing, and services of nebulizer medical technology, covering various fields such as life healthcare, clinical medicine, and nebulized vaccines.
feellife® boasts a portfolio of 220+ core patents under AiMesh®, leading the innovation in intelligent variable-frequency nebulization technology. With a CNAS-certified standard laboratory, the company has successfully obtained international ISO13485 certification, national medical device Class II EU CE certification, and FDA certification in the United States. Its products are distributed across more than 60 countries and regions, including Europe, America, the Middle East, Southeast Asia, and East Asia.
Leveraging the patented AiMesh® nebulization core technology, feellife® holds a strong core competitive advantage in the international medical nebulization field. Through technological innovation driving product development, the company aims to meet the demands of nebulized medical care, contributing to the steady development of the nebulized medical sector.
In the upcoming Arab Health Exhibition, feellife® will continue to explore new trends in nebulized medical care, fully utilize its technological advantages, and actively pursue the vision of "providing a third way of dosing for humanity." The company is committed to delivering high-quality nebulized medical services and experiences to users globally.